Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 186

Sort by

Sort Order Select

Journal Articles

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh, Andrew Brunner, Diletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza, David Sallman, Eric Padron, Zhuoer Xie, James Foran, Cecilia Arana Yi, Hassan Alkhateeb, Mithun Shah, Rami Komrokji, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2025-3864

Published: 2025

Journal Articles

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Blood (2025) 146 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2025-3847

Published: 2025

Journal Articles

Quality of life and organization of care in patients with chronic myeloid leukemia (CML) within the lombardy hematologic network (REL): The CML-OPERAP study

Giacomo Mossini, Federica Colombo, Nicola Orofino, Michela Anghilieri, Elda Mimiola, Alessandra Iurlo, Rossella Calori, Cristina Fiamenghi, Laura Antolini, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2025) 146 (Supplement 1): 2827.

https://doi.org/10.1182/blood-2025-2827

Published: 2025

Journal Articles

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Blood (2025) 146 (Supplement 1): 75.

https://doi.org/10.1182/blood-2025-75

Published: 2025

Journal Articles

Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML

maria Beatrice Ferrari, Silvia Pierini, Giulia Cotilli, Fabrizio Cavalca, Giovanni Rindone, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2025) 146 (Supplement 1): 7301.

https://doi.org/10.1182/blood-2025-7301

Published: 2025

Journal Articles

The T cell immunosenescence profile of patients with newly diagnosed multiple myeloma as an indicator of frailty: Preliminary data from the immuno-NDMM protocol.

Stefano Crippa, Alessandra Perego, Sarah Tettamanti, Lisa Mercadante, Elena Tassistro, Carlo Gambacorti-Passerini, Sara Pezzatti

Blood (2025) 146 (Supplement 1): 5786.

https://doi.org/10.1182/blood-2025-5786

Published: 2025

Journal Articles

Successful Pregnancies during Crizotinib Therapy for ALK+ Lymphoma

Veronica Guglielmana, Francesco Maria Fusi, Valentina Giardini, Federica Cocito, Carlo Gambacorti-Passerini

Blood (2024) 144 (Supplement 1): 7758.

https://doi.org/10.1182/blood-2024-203580

Published: 2024

Journal Articles

Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Blood (2024) 144 (Supplement 1): 3162.

https://doi.org/10.1182/blood-2024-201493

Published: 2024

Journal Articles

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2024) 144 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2024-208504

Published: 2024

Journal Articles

Outpatient Administration of First Cycle Azacitidine-Venetoclax in Acute Myeloid Leukemia Patients Compared to Inpatient Care: Preliminary Results of a Single-Center Retro-Prospective Study

Arianna Zappaterra, Caterina Brambilla, Beatrice Manghisi, Stefano Bonfanti, Maria Kogan, Paola Perfetti, Lorenza Maria Borin, Andrea Carrer, Luisa Verga, Carlo Gambacorti-Passerini, Monica Fumagalli

Blood (2024) 144 (Supplement 1): 6053.

https://doi.org/10.1182/blood-2024-202309

Published: 2024

Journal Articles

Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors: 5-Year Update of a Phase 2 Open Label Monocentric Study

Federica Colombo, Andrea Aroldi, Stefano Crippa, Federica Cocito, Luca Guerra, Lavinia Monaco, Bianca Maria Granelli, Lara Mussolin, Carlo Gambacorti-Passerini

Blood (2024) 144 (Supplement 1): 3117.

https://doi.org/10.1182/blood-2024-206041

Published: 2024

Journal Articles

Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients during Treatment with Bosutinib

Elena Agostani, Elena Tassistro, Laura Antolini, Carlo Gambacorti-Passerini

Blood (2024) 144 (Supplement 1): 6595.

https://doi.org/10.1182/blood-2024-206023

Published: 2024

Journal Articles

Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

Blood (2024) 144 (Supplement 1): 1778.

https://doi.org/10.1182/blood-2024-200208

Published: 2024

Journal Articles

Rare Types of NPM1 Mutations Share a Similar Molecular Background to the Common NPM1 Variant and Have No Impact on Survival in Adults with Acute Myeloid Leukemia

Valentina Fabiola Ilenia Sangiorgio, Rocco Piazza, Monica Fumagalli, Carlo Gambacorti-Passerini, Mariarita Sciumè, Daniele Ramazzotti

Blood (2024) 144 (Supplement 1): 2936.

https://doi.org/10.1182/blood-2024-202884

Published: 2024

Journal Articles

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Blood (2024) 143 (14): 1399–1413.

https://doi.org/10.1182/blood.2023021349

Published: 2024

Includes: Supplemental data

Journal Articles

Evaluating the Performance of Large Language Models in Hematopoietic Stem Cell Transplantation Decision Making

Ivan Civettini, Arianna Zappaterra, Daniele Ramazzotti, Bianca Maria Granelli, Giovanni Rindone, Andrea Aroldi, Stefano Bonfanti, Federica Colombo, Marilena Fedele, Giovanni Grillo, Matteo Parma, Paola Perfetti, Elisabetta Terruzzi, Carlo Gambacorti-Passerini, Fabrizio Cavalca

Blood (2023) 142 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2023-185854

Published: 2023

Journal Articles

Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors

Alessia Ripamonti, Andrea Aroldi, Federica Cocito, Luca Guerra, Lavinia Monaco, Bianca Maria Granelli, Lara Mussolin, Carlo Gambacorti-Passerini

Blood (2023) 142 (Supplement 1): 4474.

https://doi.org/10.1182/blood-2023-186702

Published: 2023

Journal Articles

Oral Anticoagulant Therapy in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Real-Life Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants

Fabrizio Cavalca, Ivan Civettini, Stefano Bonfanti, Carlo Gambacorti-Passerini, Elena Maria Elli

Blood (2023) 142 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2023-187139

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Quality of life and organization of care in patients with chronic myeloid leukemia (CML) within the lombardy hematologic network (REL): The CML-OPERAP study

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

Chemotherapy free ponatinib + asciminib achieves optimal disease controlpreallohsct in advanced – CML

The T cell immunosenescence profile of patients with newly diagnosed multiple myeloma as an indicator of frailty: Preliminary data from the immuno-NDMM protocol.

Successful Pregnancies during Crizotinib Therapy for ALK+ Lymphoma

Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Outpatient Administration of First Cycle Azacitidine-Venetoclax in Acute Myeloid Leukemia Patients Compared to Inpatient Care: Preliminary Results of a Single-Center Retro-Prospective Study

Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors: 5-Year Update of a Phase 2 Open Label Monocentric Study

Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients during Treatment with Bosutinib

Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

Rare Types of NPM1 Mutations Share a Similar Molecular Background to the Common NPM1 Variant and Have No Impact on Survival in Adults with Acute Myeloid Leukemia

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Evaluating the Performance of Large Language Models in Hematopoietic Stem Cell Transplantation Decision Making

Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors

Oral Anticoagulant Therapy in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Real-Life Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only